Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Noteable ---is this more harry houdini stuff?
View:
Post by HCallahann44 on Sep 22, 2021 11:59am

Noteable ---is this more harry houdini stuff?

https://www.griproom.com/fun/early-use-of-remdesivir-reduces-hospitalization-by-87 Guys---I am a long suffering ONCY share holder...please do some DD on MTNB---this is the real thing...not like the pretender we have all been invested in for years now. I will hold my ONCY for now...but I am throwing every other penny into MTNB---their LNC delivery tech may disrupt the drug industry....Comments welcome..
Comment by Noteable on Sep 22, 2021 4:23pm
The Giled remdesivir study was meant to test whether giving remdesivir earlier could have a bigger effect on Covid-19. But Gilead stopped it in April 2021 when it had only enrolled about half of the expected number of patients.  The new results, which were issued in a press release today, could help shore up the perception that the medicine is effective but that is not entirely conclusive ...more  
Comment by HCallahann44 on Sep 22, 2021 6:18pm
exactly Notable...but you have not been reading my links... MTNB solves this problem with an oral delivery system...that allows potentially toxic meds to be taken orally...they system may replace vaccines...and maybe even injected insulin...If LNC is validated...MTNB will fly out of the solar system....based on the licensing revenue it will receive from every big pharma on the planet....forget ...more  
Comment by Noteable on Sep 22, 2021 7:44pm
MTNB's technology utilizes lipid nano-crystals that encapsulate small molecule drugs and has limited application in the precision delivery and release of the contents at the target site, thus leading to either to clearance from the body or off-site toxcitity due to off-target activation.  While this technology may be useful for oral small molecule medications that are absorbed in the gut ...more  
Comment by Noteable on Sep 22, 2021 9:36pm
Harry, .... MTNB's technology may be a potential solution for an oral remdesivir, which is an antiviral once infected. This technology will not replace vaccine injections since vaccines work by mounting the needed immune response to develop antibodies to a specific antigen which then prevents a viral infection from taking hold in the first place. As such, I am not aware of any vaccine that can ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities